id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-E-2224-0007,FDA,FDA-2020-E-2224,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-08-29T04:00:00Z,2022,8,2022-08-29T04:00:00Z,,2022-08-29T15:51:52Z,,0,0,0900006485286640
FDA-2020-E-2224-0006,FDA,FDA-2020-E-2224,Determination of Regulatory Review Period for Purposes of Patent Extension; ZEPZELCA,Notice,Determinations,2021-11-30T05:00:00Z,2021,11,2021-11-30T05:00:00Z,2022-02-01T04:59:59Z,2024-02-05T18:15:56Z,2021-26009,0,0,0900006484e8c17a
FDA-2020-E-2224-0005,FDA,FDA-2020-E-2224,Patent Term Extension Approval letter from FDA CDER,Other,Approval,2021-11-05T04:00:00Z,2021,11,2021-11-05T04:00:00Z,,2021-11-05T15:22:44Z,,0,0,0900006484e25944
FDA-2020-E-2224-0004,FDA,FDA-2020-E-2224,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2021-07-26T04:00:00Z,2021,7,2021-07-26T04:00:00Z,,2021-07-26T18:00:19Z,,0,0,0900006484c0fcb3
FDA-2020-E-2224-0003,FDA,FDA-2020-E-2224,Letter to U S Patent and Trademark Office,Other,Letter(s),2020-12-14T05:00:00Z,2020,12,2020-12-14T05:00:00Z,,2020-12-14T20:19:24Z,,0,0,090000648499d790
FDA-2020-E-2224-0002,FDA,FDA-2020-E-2224,"Patent Term Extension Application for ZEPZELCA® Patent No 7,763,615",Other,Application,2020-11-24T05:00:00Z,2020,11,2020-11-24T05:00:00Z,,2020-11-24T16:25:07Z,,0,0,0900006484973f4e
FDA-2020-E-2224-0001,FDA,FDA-2020-E-2224,Letter from U S Patent and Trademark Office,Other,Letter(s),2020-11-24T05:00:00Z,2020,11,2020-11-24T05:00:00Z,,2020-11-24T16:24:09Z,,0,0,0900006484973f4d